Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

5-hydroxymethyl -2-furol and its derivative analogue medical use

A kind of use, methyl technology, applied in the field of medical use of 5-hydroxymethyl-2-furfural and its derivatives, analogues, can solve undisclosed problems

Inactive Publication Date: 2009-08-19
HUTCHISON MEDIPHARMA ENTERPRISES LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The existing literature also does not disclose methyl 2-methyl-3-furanoate, furfuryl acetate, 5-methyl-2-furfural, 2-acetyl-5-methylfuran, 5-ethyl-2-furfural , 5-amino-2-furan-methyl formate, 5-ethyl-2-thiophene aldehyde and other derivatives and analogs of 5-hydroxymethyl-2-furfural have the activity of inhibiting the expression of TNFα and IL-1β

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-hydroxymethyl -2-furol and its derivative analogue medical use
  • 5-hydroxymethyl -2-furol and its derivative analogue medical use
  • 5-hydroxymethyl -2-furol and its derivative analogue medical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1 Separation and identification of 5-hydroxymethyl-2-furfural (5-HMF)

[0071] 500 g of Cornus officinalis was extracted 3 times with slightly boiling 0.36% hydrochloric acid aqueous solution (5000 mL), 2 hours each time. The three extracts were combined and filtered. The filtrate was passed through a HP-20 macroporous resin adsorption column (6.5×100 mm), and then eluted with water, 10% ethanol, and 15% ethanol in sequence. The 15% ethanol eluate was concentrated, then purified by RP-18 column, and water was used as eluent. After the eluate was concentrated, it was purified with a Gilson semi-preparative HPLC instrument [Zorbax C18 column (9.4×250mm)], and the mobile phase was CH 3 OH / H 2 O(8 / 92), the flow rate was 8 mL / min, and the fraction with a retention time of 5 minutes was collected and dried to obtain 100 mg of compound 5-hydroxymethyl-2 furfural (yield 0.02%).

[0072] UV(λ max , nm): 284, 230, 195;

[0073] IR (cm -1 , KBr): 3350, 1673, 1522, 1...

Embodiment 2

[0077] Example 2 5-Hydroxymethyl-2-furfural inhibits the expression of inflammatory factors in vitro

[0078] Experimental Materials:

[0079] 1. Cells: peripheral blood mononuclear cells

[0080] 2. Test drug: 5-hydroxymethyl-2-furfural (5-HMF)

[0081] 3. Positive control: dexamethasone

[0082] 4. Reagents: Ficoll-Paque Plus (Amersham Bioscience); endotoxin (LPS, lipopolysaccharide) and dexamethasone (CalBiochem.); TNFa ELISA Kit and IL-1βELISA Kit (Jingmei Bioengineering Company); DMSO (Sigma).

[0083] Method and Results:

[0084] Fresh blood was treated with EDTA as an anticoagulant, and peripheral blood mononuclear cells were separated and suspended in RIMP 1640 medium containing 10% FBS. Add 100 μl to a density of 1 x 10 in a 96-well plate 5 Cells / ml of freshly isolated cells, the total number of cells per well is 10 4 3 holes for each sample.

[0085] 1) Add specified concentrations of 5-hydroxymethyl-2-furfural (final concentrations are 3, 10, 30, 100, 300ug / m...

Embodiment 3

[0095] Embodiment 3 Preparation of (embodiment 1) tablet containing 5-hydroxymethyl-2-furfural

[0096] 5-Hydroxymethyl-2-furfural 30g

[0097] Starch 3g

[0098] Appropriate amount of starch slurry (10%)

[0099] Citric acid 0.15g

[0100] Talc powder 1.5g

[0101] Mix 5-hydroxymethyl-2-furfural with starch evenly, add 8% starch slurry to make software, granulate with 14-mesh nylon sieve, dry at 70-80°C, granulate through 10-12 mesh wire sieve, and mix with talc After the powder is mixed, it is pressed into tablets with a 12mm die.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the medical use of the compound of general formula I or its pharmaceutically acceptable salt, prodrug, specifically relates to the compound of general formula I or its pharmaceutically acceptable salt, prodrug in the preparation treatment of TNF-α or IL-1β related diseases Use in medicine: where, X represents oxygen or sulfur; Y represents hydrogen, hydroxyl, C1-4 alkyl or C1-4 alkoxy; Z represents hydrogen, C1-4 alkyl, C1-4 alkoxy, amino , C1-4 alkylamino or hydroxyl C1-4 alkyl; A represents hydrogen, C1-4 alkyl or C1-4 alkoxy; B represents C1-4 alkylene, oxy C1-4 alkylene, C1 -4 alkyleneoxy or bond.

Description

technical field [0001] The present invention relates to the medical use of 5-hydroxymethyl-2-furfural and its derivatives and analogues, in particular to 5-hydroxymethyl-2-furfural and its derivatives, analogues and their pharmaceutically acceptable salts, precursors Use of the medicine in the preparation of medicines for treating TNF-α or IL-1β related diseases. . Background technique [0002] Inflammation is the body's defense-based response to the damage caused by various inflammatory factors. The local manifestations of inflammation are redness, swelling, heat, pain and dysfunction. These manifestations are more obvious in acute body surface inflammation, but less obvious in visceral inflammation and chronic inflammation. Inflammation is not only local, but also often causes systemic reactions. Common systemic reactions include fever, increased leukocyte count in the blood, and varying degrees of degeneration and necrosis of heart, liver, kidney and other solid organs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/341A61K31/381A61P29/00A61P19/02A61P19/00A61P9/04A61P3/10A61P3/04A61P25/28A61P25/16A61P17/00A61P11/00A61P1/18A61P1/02A61P1/00
Inventor 杜莹潘柯严孝强张维汉洪建荣
Owner HUTCHISON MEDIPHARMA ENTERPRISES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com